[Adequacy of prescribing the disaggregants in vascular pathology of the eye fundus and in primary open-angle glaucoma].
The functional activity of blood platelets was studied in 936 patients with vascular pathology of the eye fundus (central chorioretinal dystrophy--CCRD; preproliferative diabetic retinopathy--PPDR; proliferative diabetic retinopathy--PDR; hypertensive retinopathy--HP; thrombosis of retinal veins--TRV; and primary open angle glaucoma--POAG) by using 2 methods: the routine one, which does not expose the real process of platelets' aggregation in the blood bed, and a method, which is closer to the conditions in vivo. The non-physiological ("tube"-based) methods of determination of platelets' aggregation overstate almost 3-fold the share (%) of patients needing disaggregants. The disaggregation therapy is indicated in 28% of cases; it is more often prescribed for patients with TRV (52.2%), HP (40%), PPDR (35.5%), POAG (29%), PDR (21.5%) and CCRD (15.3%). An acute decrease of the aggregation ability of platelets was registered in 22.5% of the examinees: drugs intensifying the functional activity of platelets were used. The conclusion is that iatrogenic hemorrhages can be reduced by using adequate methods for the determination of the functional activity of platelets and by prescribing an adequate medicamental therapy.
Mukha
A I
AI
D015862:Choroid Diseases / Q000097:blood / Q000188:drug therapy; D003930:Diabetic Retinopathy / Q000097:blood / Q000188:drug therapy; D005654:Fundus Oculi; D005902:Glaucoma, Open-Angle / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012162:Retinal Degeneration / Q000097:blood / Q000188:drug therapy; D012164:Retinal Diseases / Q000097:blood / Q000188:drug therapy*; D012170:Retinal Vein Occlusion / Q000097:blood / Q000188:drug therapy
D010975:Platelet Aggregation Inhibitors